1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,540 | 0,580 | 21:24 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Di | RECBIO-B (02179): RESIGNATION OF DIRECTOR, SECRETARY OF THE BOARD, AUTHORISED REPRESENTATIVE AND JOINT COMPANY SECRETARY AND APPOINTMENT OF AUTHORISED ... | 2 | HKEx | ||
| JIANGSU RECBIO TECHNOLOGY Aktie jetzt für 0€ handeln | |||||
| 19.08. | RECBIO-B (02179): LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS | - | HKEx | ||
| 19.08. | RECBIO-B (02179): UNAUDITED INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED JUNE 30, 2026 AND ADJUSTMENT TO THE COMPOSITION OF THE AUDIT COMMITTEE | - | HKEx | ||
| 17.08. | RECBIO-B (02179): ARTICLES OF ASSOCIATION | 1 | HKEx | ||
| 17.08. | RECBIO-B (02179): AMENDMENTS TO THE ARTICLES OF ASSOCIATION | - | HKEx | ||
| 07.08. | RECBIO-B (02179): DATE OF BOARD MEETING | - | HKEx | ||
| 31.07. | RECBIO-B (02179): ANNOUNCEMENT ON THE ESTIMATED RESULTS FOR THE FIRST HALF OF 2026 | 1 | HKEx | ||
| 23.07. | RECBIO-B (02179): VOLUNTARY ANNOUNCEMENT LATEST BUSINESS DEVELOPMENTS RELATING TO THE SHINGLES VACCINE AND HPV 9-VALENT VACCINE | - | HKEx | ||
| 28.05. | RECBIO-B (02179): POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON MAY 28, 2026 | - | HKEx | ||
| 30.04. | RECBIO-B (02179): NEXT DAY DISCLOSURE RETURN | 1 | HKEx | ||
| 30.04. | RECBIO-B (02179): INSIDE INFORMATION ANNOUNCEMENT COMPLETION OF FULL CIRCULATION OF H SHARES | 3 | HKEx | ||
| 29.04. | RECBIO-B (02179): FORM OF PROXY FOR USE AT THE 2025 ANNUAL GENERAL MEETING TO BE HELD ON THURSDAY, MAY 28, 2026 | - | HKEx | ||
| 29.04. | RECBIO-B (02179): NOTICE OF 2025 ANNUAL GENERAL MEETING | - | HKEx | ||
| 29.04. | RECBIO-B (02179): CIRCULAR OF 2025 ANNUAL GENERAL MEETING | - | HKEx | ||
| 29.04. | RECBIO-B (02179): 2025 ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT | - | HKEx | ||
| 29.04. | RECBIO-B (02179): 2025 ANNUAL REPORT | 1 | HKEx | ||
| 24.03. | RECBIO-B (02179): ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2025 AND PROPOSED CHANGE OF THE USE OF PROCEEDS | 1 | HKEx | ||
| 24.03. | RECBIO-B (02179): CHANGE OF JOINT COMPANY SECRETARIES, AUTHORISED REPRESENTATIVE AND PROCESS AGENT | 1 | HKEx | ||
| 12.03. | RECBIO-B (02179): DATE OF BOARD MEETING | - | HKEx |
19 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 37,750 | +1,10 % | DAX Gewinner am Mittwoch: Qiagen Aktie | Kursentwicklung und Chartanalyse | ||
| CELULARITY | 2,070 | +140,70 % | Celularity Inc.: Celularity Provides Update Regarding Nasdaq Listing Compliance | FLORHAM PARK, N.J., Aug. 25, 2026 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (the "Company") today announced that, on August 21, 2026, it received a notification letter from the Listing Qualifications... ► Artikel lesen | |
| VERA THERAPEUTICS | 34,580 | -6,08 % | Weekly Buzz: Johnson & Johnson, Vera Therapeutics Get FDA Nod; Vertex Pharmaceuticals Snaps Up Crinetics Pharmaceuticals; Satellos Bioscience Aces DMD Trial; Ionis Pharmaceuticals Misses Key Goal | NEW BRUNSWICK (dpa-AFX) - This week featured a steady stream of regulatory milestones, strategic dealmaking, and pivotal clinical trial updates, alongside missed trial goals across the biotech... ► Artikel lesen | |
| ERASCA | 19,430 | +1,52 % | Erasca, Inc. - 8-K, Current Report | ||
| PROPANC BIOPHARMA | 2,330 | +117,76 % | Propanc Biopharma, Inc.: Propanc Biopharma Announces Compelling New Preclinical Pancreatic Cancer Data for PRP Showing >90% Tumor Growth Inhibition and >2.5-Fold Survival Benefit | MELBOURNE, Australia, Aug. 27, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) ("Propanc" or the "Company"), a biopharmaceutical company focused on developing novel treatments for... ► Artikel lesen | |
| APOGEE THERAPEUTICS | 134,97 | +0,02 % | Apogee Therapeutics: Apogee Reports Second Quarter 2026 Financial Results and Recent Corporate and Pipeline Updates | AbbVie to acquire Apogee for $135.11 per share in cash for total equity value of approximately $10.9 billion, positioning differentiated immunology portfolio to reach more patients worldwide Positive... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 14,270 | +0,28 % | Summit Therapeutics Partner Highlights Positive Interim Data Milestone for Lead Cancer Therapy | ||
| MODERNA | 119,60 | -6,90 % | Moderna-Aktie explodiert: Revolutionärer Krebsimpfstoff sorgt für Börsenrallye - BioNTech profitiert | Eine bahnbrechende Krebsstudie katapultiert den Moderna-Kurs an der Nasdaq in neue Höhen und entfacht auch ein Kursfeuerwerk bei BioNTech. Die mRNA-Technologie steht vor einem historischen Durchbruch... ► Artikel lesen | |
| COGENT BIOSCIENCES | 37,170 | +1,23 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Submission of New Drug Application (NDA) for Bezuclastinib in Advanced Systemic Mastocytosis (AdvSM) | Submission based on results of APEX pivotal trial which demonstrated bezuclastinib objective response rate (CR+CRh+PR+CI) of 65% per mIWG criteria and 81% ORR per PPR criteria with a well-tolerated... ► Artikel lesen | |
| TANGO THERAPEUTICS | 25,400 | -0,31 % | Tango Therapeutics, Inc.: Tango Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Highlights | Company continues to prepare for late-stage clinical advancement of vopimetostat in combination with daraxonrasib for pancreatic cancer following positive Phase 1/2 data Phase 1/2 data from combination... ► Artikel lesen | |
| KYMERA THERAPEUTICS | 120,70 | -3,81 % | Kymera International Appoints Willson Ropp as Chief Executive Officer | Experienced specialty materials executive brings more than 30 years of leadership experience across global manufacturing, operational excellence, business integration, and long-term value... ► Artikel lesen | |
| BIONTECH | 95,55 | -1,09 % | Noerr berät DUBAG beim Erwerb von JPT Peptide Technologies von BioNTech | ||
| AMYLYX PHARMACEUTICALS | 37,540 | +1,30 % | Guggenheim raises Amylyx stock price target on financing, trial data | ||
| ENLIVEN THERAPEUTICS | 60,58 | -0,38 % | Enliven Therapeutics, Inc.: Enliven Therapeutics Announces Pricing of Upsized Public Offering of Common Stock and Pre-Funded Warrants | BURLINGAME, Calif., June 11, 2026 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company... ► Artikel lesen | |
| RELAY THERAPEUTICS | 19,325 | -0,69 % | H.C. Wainwright raises Relay Therapeutics price target to $29 |
Das Unternehmen JIANGSU RECBIO TECHNOLOGY CO LTD kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 0,500 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu JIANGSU RECBIO TECHNOLOGY CO LTD finden Sie auf Wallstreet Online.